ESTABLISHMENT LABS HOLDINGS INC. — fact timeline

ESTABLISHMENT LABS HOLDINGS INC. shareholders approved Ratification of the appointment of CBIZ, CPAs P.C. as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-05-22 meeting.

“Proposal 3 - Ratification of the Appointment of Independent Registered Public Accounting Firm . The appointment of CBIZ, CPAs P.C. as the Company’s independent registered public accounting firm for its fiscal year ending December 31, 2026 was ratified. Votes For Votes Against Abstain 22,686,230 405,748 8,461”

ESTABLISHMENT LABS HOLDINGS INC. shareholders approved Advisory approval of the compensation of the named executive officers at the 2026-05-22 meeting.

“Proposal 2 - The approval, on an advisory basis, of the compensation of the named executive officers. The compensation of the Company's named executive officers was approved, on an advisory basis. Votes For Votes Against Abstain Broker Non-votes 7078 19,999,556 30,543 7,078 3,063,262”

ESTABLISHMENT LABS HOLDINGS INC. shareholders approved Election of Directors at the 2026-05-22 meeting.

“Proposal 1 - Election of Directors . The following nominees were elected as directors to serve until the Company's 2027 Annual Meeting of Shareholders and until their successors are duly elected and qualified: Nominee Votes For Votes Against Abstain Broker Non-votes Filippo "Peter" Caldini 20,009,113 21,173 6,891 3,063,262 Ann Custin 19,788,813 39,815 208,549 3,063,262 Leslie Gillin 18,323,390 1,706,838 6,949 3,063,262 Nicholas Lewin 17,288,905 2,741,365 6,907 3,063,262 Edward Schutter 20,001,165 29,105 6,907 3,063,262 Bryan Slotkin 17,495,042 2,535,178 6,957 3,063,262”

ESTABLISHMENT LABS HOLDINGS INC. reported the first quarter ended March 31, 2026 results: revenue $59.9 million, net income $13.4 million. Guidance raised.

“breast aesthetics and reconstruction, today announced financial results for the first quarter ended March 31, 2026. First Quarter Highlights and Outlook (Unaudited) • Revenue of $59.9 million, up 44.7% from Q1 2025, with guidance raised to $266.5 million to $268.5 million • $19.6 million of Motiva sales in the United States, up 13.3% from Q4 2025 • Minimally invasive”

ESTABLISHMENT LABS HOLDINGS INC. incurred term loan of an aggregate principal amount of up to $300,000,000 with Oaktree Fund Administration, LLC (as administrative agent) and the Lenders at 8.75% per annum maturing April 30, 2031.

“On April 30, 2026 (the “Closing Date”), Establishment Labs Holdings Inc. (the “Company”) entered into an Amended Credit Agreement and Guaranty (the “Credit Agreement”) together with certain of its subsidiaries party thereto as guarantors, the lenders from time to time party thereto (the “Lenders”), and Oaktree Fund Administration, LLC, as administrative agent for the Lenders (in such capacity, the “Administrative Agent”), pursuant to which the Lenders agreed to make term loans to the Company in an aggregate principal amount of up to $300,000,000 (the “Term Loans”). The Credit Agreement amended and restated that certain Credit Agreement and Guaranty dated as of April, 26 2022 (as amended from time to time) (the “Prior Credit Agreement”), by and among the Company, its subsidiaries party thereto as guarantors, the lenders party thereto and Oaktree Fund Administration, LLC, as administrative agent. The proceeds of the Term Loans will be used for (a) repayment of outstanding indebtedness un”

ESTABLISHMENT LABS HOLDINGS INC. amended Amended Credit Agreement and Guaranty with Oaktree Fund Administration, LLC valued at $300,000,000 term loans (effective 2026-04-30).

“On April 30, 2026 (the “Closing Date”), Establishment Labs Holdings Inc. (the “Company”) entered into an Amended Credit Agreement and Guaranty (the “Credit Agreement”) together with certain of its subsidiaries party thereto as guarantors, the lenders from time to time party thereto (the “Lenders”), and Oaktree Fund Administration, LLC, as administrative agent for the Lenders (in such capacity, the “Administrative Agent”), pursuant to which the Lenders agreed to make term loans to the Company in an aggregate principal amount of up to $300,000,000 (the “Term Loans”).”

ESTABLISHMENT LABS HOLDINGS INC. incurred term loan of $25,000,000 with Oaktree Fund Administration, LLC.

“On September 29, 2025, the Company fully borrowed the Tranche D Term Loans available under the Agreement in an amount equal to $25,000,000.”

Marcum LLP resigned as auditor of ESTABLISHMENT LABS HOLDINGS INC..

“Accordingly, on May 20, 2025, as a result of the acquisition, Marcum resigned as the independent registered public accounting firm of Establishment Labs Holdings, Inc. (the “Company”) and, on the same day, the Audit Committee of the Company’s Board of Directors (the “Audit Committee”) approved the appointment of CBIZ as the Company’s independent registered public accounting firm.”

Fillipo "Peter" Caldini was appointed as Class II Director at ESTABLISHMENT LABS HOLDINGS INC..

“The Board also appointed Mr. Caldini as a Class II director of the Company, effective May 24, 2025.”

Fillipo "Peter" Caldini was appointed as Chief Executive Officer at ESTABLISHMENT LABS HOLDINGS INC..

“appointed the Company’s interim Chief Executive Officer Fillipo “Peter” Caldini to serve as Chief Executive Officer, effective May 7, 2025.”

Fillipo "Peter" Caldini was appointed as Interim CEO at ESTABLISHMENT LABS HOLDINGS INC..

“Fillipo “Peter” Caldini, the Company’s current President, will serve as Interim CEO as of March 1, 2025.”

Juan José Chacón-Quirós retired as Chief Executive Officer at ESTABLISHMENT LABS HOLDINGS INC..

“Juan José Chacón-Quirós, the Company’s Chief Executive Officer, has provided notice of his decision to retire from his position as Chief Executive Officer, effective on March 1, 2025.”

Fillipo "Peter" Caldini was appointed as President at ESTABLISHMENT LABS HOLDINGS INC..

“On August 20, 2024, the Board of Directors of Establishment Labs Holdings Inc. (the “Company”) appointed Fillipo “Peter” Caldini to the position of President of the Company effective immediately (the “Start Date”).”

ESTABLISHMENT LABS HOLDINGS INC. reported the three months ended March 31, 2024 results: revenue $37.2 million, net income $16.2 million. Guidance reaffirmed.

“and reconstruction, today announced financial results for the first quarter ended March 31, 2024. First Quarter Highlights and Outlook • First quarter worldwide revenue of $37.2 million. • 2024 revenue guidance remains $174 million to $184 million, an increase of 5% to 11% over 2023. Guidance does not include revenue from Motiva Implants ® in the United States,”

ESTABLISHMENT LABS HOLDINGS INC. reported 2024 results: revenue $174 million to $184 million. Guidance reaffirmed.

“2024 revenue guidance of $174 million to $184 million, an increase of 5% to 11% over 2023.”

ESTABLISHMENT LABS HOLDINGS INC. reported Fourth Quarter 2023 results: net income $22.1 million net loss.

“Fourth quarter net loss from operations of $22.1 million compared to a net loss of $13.2 million in the year-ago period.”

ESTABLISHMENT LABS HOLDINGS INC. reported Fourth Quarter and Full Year 2023 results: revenue $31.6 million.

“Total revenue for the quarter ended December 31, 2023 was $31.6 million compared to $43.8 million for the same period in 2022.”

ESTABLISHMENT LABS HOLDINGS INC. amended Second Amendment to Credit Agreement and Guaranty with Oaktree Fund Administration, LLC, as administrative agent, and the other parties thereto (effective 2024-02-21).

“On February 21, 2024, Establishment Labs Holdings Inc. (the “Company”) entered into a Second Amendment to Credit Agreement and Guaranty with Oaktree Fund Administration, LLC, as administrative agent, and the other parties thereto (the “Amendment”), which amends the terms of that certain Credit Agreement and Guaranty, dated as of April 26, 2022”

ESTABLISHMENT LABS HOLDINGS INC. reported fourth quarter and fiscal year 2023 results: revenue in the range of $31.4 million to $31.8 million. Guidance reaffirmed.

“unaudited financial results for the fourth quarter and fiscal year 2023. Preliminary unaudited revenue for the fourth quarter of 2023 is expected to be in the range of $31.4 million to $31.8 million, in line with the guidance provided on November 7 in the third quarter earnings release. Based on the expected range for fourth quarter preliminary unaudited”

ESTABLISHMENT LABS HOLDINGS INC. entered into Registration Rights Agreement with the Investors (effective 2024-01-09).

“In connection with the Private Placement, the Company entered into a registration rights agreement, dated January 9, 2024 (the “Registration Rights Agreement”), with the Investors, pursuant to which, among other things, the Company will (i) prepare and file with the Securities and Exchange Commission (the “SEC”) a registration statement on Form S-3 (or a prospectus supplement to the Company’s Form S-3 (File No. 333-271418)) to register for resale the Shares and the Common Shares issuable upon the exercise of the Pre-Funded Warrants within 30 calendar days of the closing of the Private Placement, and (ii) use commercially reasonable efforts to have the registration statement declared effective, if not automatically effective upon filing, as soon as reasonably practicable after such registration statement has been filed with the SEC.”

ESTABLISHMENT LABS HOLDINGS INC. entered into Securities Purchase Agreement with select institutional accredited investors valued at approximately $50 million (effective 2024-01-09).

“On January 9, 2024, Establishment Labs Holdings Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with select institutional accredited investors (the “Investors”), pursuant to which the Company agreed to issue and sell to the Investors in a private placement (the “Private Placement”) (i) an aggregate of 1,101,565 common shares (the “Shares”) of the Company, no par value per share (the “Common Shares”), and (ii) in lieu of Common Shares, pre-funded warrants providing for the purchase, upon exercise, of an aggregate of 898,435 Common Shares (the “Pre-Funded Warrants”).”

Paul D. Rodio departed as Chief Operating Officer at ESTABLISHMENT LABS HOLDINGS INC..

“On December 8, 2023, Paul D. Rodio, the Company’s Chief Operating Officer, departed from Establishment Labs Holdings Inc.”

ESTABLISHMENT LABS HOLDINGS INC. reported third quarter ended September 30, 2023 results: revenue $38.5 million. Guidance lowered.

“and reconstruction, today announced financial results for the third quarter ended September 30, 2023. Third Quarter Highlights and Outlook • Third quarter worldwide revenue of $38.5 million increased 0.8% year-over-year. • 2023 revenue guidance updated to approximately $165 million, an increase of 2% over 2022. • Third quarter loss from operations was $21.0 million”

ESTABLISHMENT LABS HOLDINGS INC. reported financial results for six months ended June 30, 2023.

“On August 8, 2023, Establishment Labs Holdings Inc. (the “Company”) issued a press release announcing the Company’s financial results for the three and six months ended June 30, 2023 and recent corporate highlights.”

ESTABLISHMENT LABS HOLDINGS INC. reported second quarter ended June 30, 2023 results: revenue $48.6 million, net income $16.7 million. Guidance reaffirmed.

“and reconstruction, today announced financial results for the second quarter ended June 30, 2023. First Quarter Highlights and Outlook • Second quarter worldwide revenue of $48.6 million increased 18.0% year-over-year and was a new quarterly record. • 2023 revenue guidance remains $200 million to $210 million, an increase of 24% to 30% over 2022. • Second quarter”

ESTABLISHMENT LABS HOLDINGS INC.: Amended and restated the Memorandum and Articles of Association to eliminate supermajority voting requirements, replacing them with a simple majority vote.

“the supermajority vote requirements that applied to approving amendments”

ESTABLISHMENT LABS HOLDINGS INC.: Amended and restated the Memorandum and Articles of Association to declassify the board of directors, phasing in one-year terms by 2026.

“shareholders approved an amendment and restatement of the Company’s Amended and Restated Memorandum of Association and Articles of Association”

ESTABLISHMENT LABS HOLDINGS INC. shareholders approved The approval of the Amendment and Restatement of Amended and Restated Memorandum of Association and Articles of Association to Eliminate Supermajority Voting Requirements at the 2023-05-24 meeting.

“Proposal 5 - The approval of the Amendment and Restatement of Amended and Restated Memorandum of Association and Articles of Association to Eliminate Supermajority Voting Requirements. The Company’s shareholders approved the Supermajority Elimination Amendment to the Memorandum and Articles of Association. Votes For Votes Against Abstain Broker Non-votes 17,638,917 8,519 1,621 2,631,579”

ESTABLISHMENT LABS HOLDINGS INC. shareholders approved The approval of the Amendment and Restatement of Amended and Restated Memorandum of Association and Articles of Association to Declassify the Board at the 2023-05-24 meeting.

“Proposal 4 - The approval of the Amendment and Restatement of Amended and Restated Memorandum of Association and Articles of Association to Declassify the Board. The Company’s shareholders approved the Declassification Amendment to the Memorandum and Articles of Association. Votes For Votes Against Abstain Broker Non-votes 17,644,487 1,738 2,832 2,631,579”

ESTABLISHMENT LABS HOLDINGS INC. shareholders approved Ratification of the Appointment of Independent Registered Public Accounting Firm at the 2023-05-24 meeting.

“Proposal 3 - Ratification of the Appointment of Independent Registered Public Accounting Firm . The appointment of Marcum LLP as the Company’s independent registered public accounting firm for its fiscal year ending December 31, 2023 was ratified. Votes For Votes Against Abstain 19,179,436 1,100,654 546”

ESTABLISHMENT LABS HOLDINGS INC. shareholders approved The approval, on an advisory basis, of the compensation of the named executive officers. at the 2023-05-24 meeting.

“Proposal 2 - The approval, on an advisory basis, of the compensation of the named executive officers. The compensation of the Company's named executive officers was approved, on an advisory basis. Votes For Votes Against Abstain Broker Non-votes 17,132,043 515,786 1,228 2,631,579”

ESTABLISHMENT LABS HOLDINGS INC. shareholders approved Election of Directors at the 2023-05-24 meeting.

“Proposal 1 - Election of Directors . Each of the following nominees were elected as Class II directors to serve until the Company's 2026 Annual Meeting of Shareholders and until their successors are duly elected and qualified: Nominee Votes For Votes Against Abstain Broker Non-votes Dennis Condon 14,788,698 2,563,074 297,285 2,631,579 Leslie Gillin 17,071,800 574,889 2,368 2,631,579”

ESTABLISHMENT LABS HOLDINGS INC. reported the first quarter ended March 31, 2023 results: revenue $46.5 million, net income $11.9 million. Guidance reaffirmed.

“Establishment Labs Reports Record First Quarter 2023 Financial Results NEW YORK, NY, May 8, 2023 -- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the first quarter ended March 31, 2023. First Quarter Highlights and Outlook • First quarter worldwide revenue of $46.5 million increased 21.0% year-over-year and was a new quarterly record; excluding the impact of foreign currency changes, revenue growth in the first quarter would have been 22.9%. • 2023 revenue guidance remains $200 million to $210 million, an increase of 24% to 30% over 2022. • First quarter loss from operations was $8.2 million compared to a loss of $5.6 million in the year-ago period as investment in growth initiatives increased. • Cash balance of $42.8 million as of March 31, 2023. • Completed follow-on share offering on April 27, with gross”

ESTABLISHMENT LABS HOLDINGS INC. entered into Underwriting Agreement with Jefferies LLC, J.P. Morgan Securities, LLC, Citigroup Global Markets Inc. and Cowen and Company, LLC, as representatives of the several underwriters valued at approximately $84.1 million (effective 2023-04-24).

“On April 24, 2023, Establishment Labs Holdings Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, J.P. Morgan Securities, LLC, Citigroup Global Markets Inc. and Cowen and Company, LLC, as representatives of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale (the “Offering”) of 1,100,000 common shares, no par value.”

ESTABLISHMENT LABS HOLDINGS INC. reported the first quarter of 2023 results: revenue approximately $46.5 million.

“In the three months ended March 31, 2023, the Company’s revenue is expected to be approximately $46.5 million”

ESTABLISHMENT LABS HOLDINGS INC. updated its the year ended December 31, 2022 guidance (initiated).

“The company also provided unaudited financial results for the fourth quarter and full year ended December 31, 2022 and provided 2023 guidance.”

ESTABLISHMENT LABS HOLDINGS INC. reported the quarter ended December 31, 2022 results: revenue $43.8 million, net income $13.6 million. Guidance initiated.

“Total revenue for the quarter ended December 31, 2022 was $43.8 million compared to $35.3 million for the same period in 2021.”

ESTABLISHMENT LABS HOLDINGS INC. reported the three months and fiscal year ended December 31, 2022 results: revenue in the range of $43.3 million to $44.3 million.

“Establishment Labs Announces Preliminary Unaudited Revenue for Fourth Quarter and Fiscal Year 2022 • Fourth-quarter revenue is expected to be in the range of $43.3 million to $44.3 million, representing growth of 23% to 25% over the same period in 2021; excluding the effects of changes in foreign currency exchange rates, growth in the fourth”

Paul D. Rodio was appointed as Chief Operating Officer at ESTABLISHMENT LABS HOLDINGS INC..

“The Board of Directors of Establishment Labs Holdings Inc. (the “Company”) has appointed Paul D. Rodio to the position of Chief Operating Officer of the Company.”

ESTABLISHMENT LABS HOLDINGS INC. reported the third quarter ended September 30, 2022 results: revenue $38.2 million, net income Net loss from operations for the third quarter was $10.5 million.

“and reconstruction, today announced its financial results for the third quarter ended September 30, 2022. Third Quarter Highlights and Outlook • Third quarter worldwide sales of $38.2 million, an increase of 31.7% year-over-year; excluding the impact of foreign currency changes, revenue growth in the third quarter would have been 37.7%. • Revenue guidance for 2022”

Pratip Dastidar departed as Head of Global Operations at ESTABLISHMENT LABS HOLDINGS INC..

“On August 19, 2022, Pratip Dastidar, the Company’s Head of Global Operations, will depart from Establishment Labs Holdings Inc.”

Lisa Gersh resigned as Director at ESTABLISHMENT LABS HOLDINGS INC..

“On March 1, 2022, Lisa Gersh notified Establishment Labs Holdings Inc. (the “Company”) that she will resign as a member of the Company's Board of Directors, effective March 31, 2022.”

Raj Denhoy was appointed as Chief Financial Officer at ESTABLISHMENT LABS HOLDINGS INC..

“On December 8, 2021, the Board of Directors (the “Board”) of Establishment Labs Holdings Inc. (the “Company”) appointed Raj Denhoy as the Company’s permanent Chief Financial Officer, effective immediately.”

Leslie Gillin was appointed as Class II Director at ESTABLISHMENT LABS HOLDINGS INC..

“On December 8, 2021, the Board of Directors (the “Board”) of Establishment Labs Holdings Inc. (the “Company”) appointed Leslie Gillin to the Board as a Class II director, effective immediately”

Bryan Slotkin was appointed as Director at ESTABLISHMENT LABS HOLDINGS INC..

“On July 13, 2021, the Board of Directors (the “Board”) of Establishment Labs Holdings Inc. (the “Company”) appointed Ms. Ann Custin and Mr. Bryan Slotkin to the Board, effective immediately.”

Ann Custin was appointed as Director at ESTABLISHMENT LABS HOLDINGS INC..

“On July 13, 2021, the Board of Directors (the “Board”) of Establishment Labs Holdings Inc. (the “Company”) appointed Ms. Ann Custin and Mr. Bryan Slotkin to the Board, effective immediately.”

Raj Denhoy was appointed as interim Chief Financial Officer at ESTABLISHMENT LABS HOLDINGS INC..

“The Company also announced that Raj Denhoy, age 51, has been appointed as the Company’s interim Chief Financial Officer, effective as of the close of business on July 30, 2021.”

Renee M. Gaeta resigned as Chief Financial Officer at ESTABLISHMENT LABS HOLDINGS INC..

“On July 7, 2021, Renee M. Gaeta informed Establishment Labs Holdings Inc. (the "Company") that she intended to resign from her position as Chief Financial Officer and subsequently communicated the effective date of the resignation of July 30, 2021.”